Patents by Inventor Shelby ELLERY
Shelby ELLERY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11945807Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: GrantFiled: May 3, 2022Date of Patent: April 2, 2024Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
-
Patent number: 11926619Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.Type: GrantFiled: April 8, 2019Date of Patent: March 12, 2024Assignee: Eisai R & D Management Co., Ltd.Inventors: Gregg F. Keaney, John Wang, Baudouin Gerard, Kenzo Arai, Xiang Liu, Guo Zhu Zheng, Kazunobu Kira, Lisa A. Marcaurelle, Marta Nevalainen, Ming-Hong Hao, Morgan Welzel O'Shea, Parcharee Tivitmahaisoon, Sudeep Prajapati, Tuoping Luo, Nicholas C. Gearhart, Jason T. Lowe, Yoshihiko Kotake, Satoshi Nagao, Regina Mikie Kanada Sonobe, Masayuki Miyano, Norio Murai, Andrew Cook, Shelby Ellery, Atsushi Endo, James Palacino, Dominic Reynolds
-
Publication number: 20230301990Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.Type: ApplicationFiled: March 7, 2023Publication date: September 28, 2023Applicant: Eisai R&D Management Co., Ltd.Inventors: Andrew COOK, Dominic REYNOLDS, Cheng ZHONG, Ryan BRAWN, Shelby ELLERY, Thiwanka SAMARAKOON, Xiang LIU, Sudeep PRAJAPATI, Megan SHEEHAN, Jason T. LOWE, James PALACINO
-
Patent number: 11679107Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful.Type: GrantFiled: April 11, 2019Date of Patent: June 20, 2023Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Andrew Cook, Dominic Reynolds, Cheng Zhong, Ryan Brawn, Shelby Ellery, Thiwanka Samarakoon, Xiang Liu, Sudeep Prajapati, Megan Sheehan, Jason T. Lowe, James Palacino
-
Publication number: 20220380352Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: ApplicationFiled: May 3, 2022Publication date: December 1, 2022Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong XIAO
-
Patent number: 11352348Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: GrantFiled: November 30, 2020Date of Patent: June 7, 2022Assignee: EISAI R&D MANAGEMENT CO., LTD.Inventors: Ermira Pazolli, Silvia Buonamici, Thiwanka Samarakoon, Sudeep Prajapati, Nathan Fishkin, James Palacino, Michael Seiler, Ping Zhu, Andrew Cook, Peter Smith, Xiang Liu, Shelby Ellery, Dominic Reynolds, Lihua Yu, Zhenhua Wu, Shouyong Peng, Nicholas Calandra, Megan Sheehan, Yonghong Xiao
-
Publication number: 20210299269Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: ApplicationFiled: May 31, 2019Publication date: September 30, 2021Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong Xiao
-
Publication number: 20210177837Abstract: The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy.Type: ApplicationFiled: April 11, 2019Publication date: June 17, 2021Applicant: Eisai R&D Management Co., Ltd.Inventors: Andrew COOK, Dominic REYNOLDS, Cheng ZHONG, Ryan BRAWN, Shelby ELLERY, Thiwanka SAMARAKOON, Xiang LIU, Sudeep PRAJAPATI, Megan SHEEHAN, Jason T. LOWE, James PALACINO
-
Publication number: 20210163456Abstract: The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.Type: ApplicationFiled: April 8, 2019Publication date: June 3, 2021Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Gregg F. KEANEY, John WANG, Baudouin GERARD, Kenzo ARAI, Xiang LIU, Guo Zhu ZHENG, Kazunobu KIRA, Lisa A. MARCAURELLE, Marta NEVALAINEN, Ming-Hong HAO, Morgan Welzel O'SHEA, Parcharee TIVITMAHAISOON, Sudeep PRAJAPATI, Touping LUO, Nicholas C. GEARHART, Jason T. LOWE, Yoshihiko KOTAKE, Satoshi NAGAO, Regina Mikie KANADA SONOBE, Masayuki MIYANO, Norio MURAI, Andrew COOK, Shelby ELLERY, Atsushi ENDO, James PALACINO, Dominic REYNOLDS
-
Publication number: 20210101888Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.Type: ApplicationFiled: November 30, 2020Publication date: April 8, 2021Inventors: Ermira PAZOLLI, Silvia BUONAMICI, Thiwanka SAMARAKOON, Sudeep PRAJAPATI, Nathan FISHKIN, James PALACINO, Michael SEILER, Ping ZHU, Andrew COOK, Peter SMITH, Xiang LIU, Shelby ELLERY, Dominic REYNOLDS, Lihua YU, Zhenhua WU, Shouyong PENG, Nicholas CALANDRA, Megan SHEEHAN, Yonghong XIAO
